Chinook Therapeutics

$10.90 0.00% ($0.00)

Get ready to invest

About Chinook Therapeutics

Chinook Therapeutics, Inc., formerly Aduro Biotech, Inc., is a clinical-stage biotechnology company. The Company develops precision medicines for kidney diseases. The Company’s products focus on severe chronic kidney disorders. The Company assembled a portfolio of precision medicines product candidates designed to address severe chronic kidney diseases. Its development programs consist of atrasentan, BION-1301 and CHK-336. Atrasentan, a potent and selective endothelin receptor antagonist that the Company is developing for treatment of primary glomerular diseases, including IgAN. IgAN is a serious progressive autoimmune disease of the kidney. BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a Phase 1b trial for IgA nephropathy. CHK-336, a preclinical development candidate for an undisclosed ultra-orphan kidney disease, as well as research programs for other chronic kidney diseases, including polycystic kidney disease.

Popular Stocks	Price	Change
Snap SNAP	$55.14 8.44%	8.44%
Intel INTC	$56 0.7%	0.7%
Itau ITUB	$4.3 0.24%	0.24%
Petrobras PBR	$10.05 1.64%	1.64%
Banco Bradesco Pref Shares BBD	$3.75 1.64%	1.64%
Ford F	$16.28 0.31%	0.31%
Cleveland-Cliffs CLF	$21.16 7.19%	7.19%
Apple AAPL	$149.48 0.52%	0.52%
Ambev ABEV	$2.63 1.95%	1.95%